nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Abbreviations and Acronyms
|
|
|
2013 |
3 |
3 |
p. x- 1 p. |
artikel |
2 |
Abstract
|
|
|
2013 |
3 |
3 |
p. 262- 1 p. |
artikel |
3 |
Acknowledgments
|
|
|
2013 |
3 |
3 |
p. 302- 1 p. |
artikel |
4 |
Biographic and disclosure information
|
|
|
2013 |
3 |
3 |
p. 297-301 5 p. |
artikel |
5 |
Chapter 1: Assessment of lipid status in adults with CKD
|
|
|
2013 |
3 |
3 |
p. 268-270 3 p. |
artikel |
6 |
Chapter 3: Assessment of lipid status in children with CKD
|
|
|
2013 |
3 |
3 |
p. 280-281 2 p. |
artikel |
7 |
Chapter 2: Pharmacological cholesterol-lowering treatment in adults
|
|
|
2013 |
3 |
3 |
p. 271-279 9 p. |
artikel |
8 |
Chapter 4: Pharmacological cholesterol-lowering treatment in children
|
|
|
2013 |
3 |
3 |
p. 282-283 2 p. |
artikel |
9 |
Chapter 5: Triglyceride-lowering treatment in adults
|
|
|
2013 |
3 |
3 |
p. 284-285 2 p. |
artikel |
10 |
Chapter 6: Triglyceride-lowering treatment in children
|
|
|
2013 |
3 |
3 |
p. 286- 1 p. |
artikel |
11 |
Conversion factors of Conventional units to SI units
|
|
|
2013 |
3 |
3 |
p. ix- 1 p. |
artikel |
12 |
Current Chronic Kidney Disease (CKD) Nomenclature used by Kdigo
|
|
|
2013 |
3 |
3 |
p. viii- 1 p. |
artikel |
13 |
Foreword
|
|
|
2013 |
3 |
3 |
p. 260- 1 p. |
artikel |
14 |
Introduction: The case for updating and context
|
|
|
2013 |
3 |
3 |
p. 266-267 2 p. |
artikel |
15 |
KDIGO Board Members
|
|
|
2013 |
3 |
3 |
p. vi- 1 p. |
artikel |
16 |
Methods for guideline development
|
|
|
2013 |
3 |
3 |
p. 287-296 10 p. |
artikel |
17 |
Notice
|
|
|
2013 |
3 |
3 |
p. 259- 1 p. |
artikel |
18 |
Reference Keys
|
|
|
2013 |
3 |
3 |
p. vii- 1 p. |
artikel |
19 |
References
|
|
|
2013 |
3 |
3 |
p. 303-305 3 p. |
artikel |
20 |
Summary of Recommendation Statements
|
|
|
2013 |
3 |
3 |
p. 263-265 3 p. |
artikel |
21 |
Tables and Figures
|
|
|
2013 |
3 |
3 |
p. v- 1 p. |
artikel |
22 |
Work Group Membership
|
|
|
2013 |
3 |
3 |
p. 261- 1 p. |
artikel |